Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities.
Prolonged exposure of human epidermis to excess endogenous or exogenous glucocorticoids can result in well-recognized cutaneous abnormalities. Here, we determined whether short-term glucocorticoid treatment would also display adverse effects, specifically on two key epidermal functions, permeability barrier homeostasis and stratum corneum integrity and cohesion, and the basis for such changes. In humans 3 d of treatment with a potent, commonly employed topical glucocorticoid (clobetasol), applied topically, produced a deterioration in barrier homeostasis, characterized by delayed barrier recovery and abnormal stratum corneum integrity (rate of barrier disruption with tape strippings) and stratum corneum cohesion (microg protein removed per stripping). Short-term systemic and topical glucocorticoid produced similar functional defects in mice, where the basis for these abnormalities was explored further. Both the production and secretion of lamellar bodies were profoundly decreased in topical glucocorticoid-treated mice resulting in decreased extracellular lamellar bilayers. These structural changes, in turn, were attributable to a profound global inhibition of lipid synthesis, demonstrated both in epidermis and in cultured human keratinocytes. The basis for the abnormality in stratum corneum integrity and cohesion was a diminution in the density of corneodesmosomes in the lower stratum corneum. We next performed topical replacement studies to determine whether lipid deficiency accounts for the glucocorticoid-induced functional abnormalities. The abnormalities in both permeability barrier homeostasis and stratum corneum integrity were corrected by topical applications of an equimolar distribution of free fatty acids, cholesterol, and ceramides, indicating that glucocorticoid-induced inhibition of epidermal lipid synthesis accounts for the derangements in both cutaneous barrier function and stratum corneum integrity/cohesion. These studies indicate that even short-term exposure to potent glucocorticosteroids can exert profound negative effects on cutaneous structure and function. Finally, topical replenishment with epidermal physiologic lipids could represent a potential method to reduce the adverse cutaneous effects of both topical glucocorticoid treatment and Cushing's syndrome.
Kao
Jack S
JS
Dermatology and Medical Services (Metabolism), VA Medical Center San Francisco and Department of Dermatology, University of California San Francisco, San Francisco, California, U.S.A.
Fluhr
Joachim W
JW
Man
Mao-Qiang
MQ
Fowler
Ashley J
AJ
Hachem
Jean-Pierre
JP
Crumrine
Debra
D
Ahn
Sung K
SK
Brown
Barbara E
BE
Elias
Peter M
PM
Feingold
Kenneth R
KR
D000287:Administration, Topical; D000328:Adult; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002990:Clobetasol / Q000008:administration & dosage*; D003896:Desmosomes / Q000648:ultrastructure; D004334:Drug Administration Schedule; D004817:Epidermis / Q000187:drug effects* / Q000378:metabolism* / Q000503:physiopathology / Q000648:ultrastructure; D005938:Glucocorticoids; D006706:Homeostasis / Q000187:drug effects*; D006801:Humans; D008055:Lipids / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000494:pharmacology; D008297:Male; D051379:Mice; D008812:Mice, Hairless; D008854:Microscopy, Electron; D008875:Middle Aged; D010539:Permeability / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D008055:Lipids; D002990:Clobetasol